Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice

Metabolism: Clinical and Experimental

Volumn 58, Issue 7, 2009, Pages 901-908

  Nakayama, Hitomi ^a   Otabe, Shuichi ^a   Yuan, Xiaohong ^a   Ueno, Takato ^a   Hirota, Naotoshi ^a   Fukutani, Tomoka ^a   Wada, Nobuhiko ^a   Hashinaga, Toshihiko ^a   Yamada, Kentaro ^a  

^a KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; ADIPONECTIN RECEPTOR; CYCLINE; GLUCOSE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; IMMUNOREACTIVITY; INSULIN RESISTANCE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; TRANSGENIC MOUSE;

ADIPONECTIN; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOTTING, NORTHERN; BLOTTING, WESTERN; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HISTOCYTOCHEMISTRY; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PPAR ALPHA; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, ADIPONECTIN; RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 66349089511     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.03.004     Document Type: Article

References (31)

1. Byron D., and Minuk G.Y. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 24 (1996) 813-815
2. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 1649-1657
3. Mendez-Sanchez N., Villa A.R., Chavez-Tapia N.C., et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 4 (2005) 52-55
4. Ioannou G.N., Boyko E.J., and Lee S.P. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 101 (2006) 76-82
5. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980) 434-438
6. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
8. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
9. Shimomura I., Hammer R.E., Richardson J.A., et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12 (1998) 3182-3194
10. Nakayama H., Otabe S., Ueno T., et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 56 (2007) 470-475
11. Hui J.M., Hodge A., Farrell G.C., et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
12. Kaser S., Moschen A., Cayon A., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 17-21
13. Musso G., Gambino R., Biroli G., et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100 (2005) 438-446
14. Otabe S., Yuan X., Fukutani T., et al. Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab 293 (2007) E210-E218
15. Floyd R.A., Watson J.J., Wong P.K., et al. Hydroxyl free radical adduct of deoxyguanosine: sensitive detection and mechanisms of formation. Free Radic Res Commun 1 (1986) 163-172
16. Nishioka N., and Arnold S.E. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 12 (2004) 167-175
17. Xu A., Wang Y., Keshaw H., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
18. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
19. Yamauchi T., Nio Y., Maki T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13 (2007) 332-339
20. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
21. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3 (2006) 35-42
22. Diehl A.M. Nonalcoholic steatosis and steatohepatitis. IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 282 (2002) G1-G5
23. Fan C.Y., Pan J., Usuda N., et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273 (1998) 15639-15645
24. Day C.P., and James O.F. Steatohepatitis: a tale of two hits?. Gastroenterology 114 (1998) 842-845
25. Matsuzawa N., Takamura T., Kurita S., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46 (2007) 1392-1403
26. Akyol G., Dursun A., Poyraz A., et al. P53 and proliferating cell nuclear antigen (PCNA) expression in non-tumoral liver diseases. Pathol Int 49 (1999) 214-221
27. Leclercq I.A., Farrell G.C., Schriemer R., and Robertson G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37 (2002) 206-213
28. Friedman S.L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 98-105
29. Atul S., Padmini M., Xiaomin P., et al. Obese and diabetic db/db mice develop marked liver fibrosis in model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287 (2004) 1035-1043
30. Ikejima K., Okumura K., Tie L., et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res 33 (2005) 151-154
31. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946